ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company’s lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancer and other solid tumors. A number of major healthcare companies have licensed limited rights to use ImmunoGen’s ADC technology to develop anticancer therapies; it is used in Roche’s marketed product, Kadcyla.
At Levena BioPharma, we interface complex synthetic chemistry with antibody research providing our clients with the latest technologies and comprehensive services to advance ADC projects from discovery to IND. Our ADC platform encompasses: ADC screening tools; bioactive molecules (toxins) for research and in cGMP grade; optimized linker-toxins; conjugation services; ADC toxicity screening; and ADC optimization & processing.
Heidelberg Pharma GmbH is a pharmaceutical company with a dual business model: (A) Providing preclinical drug development services in general with a special focus on the development of ADCs. Heidelberg Pharma has ample experience in providing antibody-drug conjugate related services to its clients. (B) Development of novel therapeutics in oncology based on its own proprietary 2nd generation ADC technology based on a novel toxin.
Piramal Healthcare’s Antibody Drug Conjugate Business is one of the world’s leading contract development and manufacturing teams delivering early phase clinical and late phase commercial supplies. Our flexible manufacturing regime and dedication to ADC processing is why our clients choose Piramal Healthcare as their preferred partner. We seek to reduce the complexity associated with ADC processing allowing for integrated and seamless scale-up of each unique ADC program.
Merck KGaA, Darmstadt, Germany is the leading Life Science company, providing services as a strategic partner to help advance the promise of life saving therapies. With the acquisition of Sigma-Aldrich (SAFC), we now have the largest offering of products and contract manufacturing services for formulations, actives and biotechnology processes. Our joint ADC offering now includes a full range of services that spans conjugation, mAbs, linkers and payloads, process development, and much more. The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.
Abzena provides technology solutions enabling development of better biopharmaceuticals through its subsidiaries PolyTherics and Antitope. PolyTherics specializes in proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimization of the therapeutic properties of biopharmaceuticals. Antitope provides immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture.
BSP Pharmaceuticals is a Contract Development and Manufacturing Organization fully dedicated to antineoplastic drugs, designed to handle the complexity of biopharmaceutical products and offering customized services to support its client from development to commercial manufacturing of injectables and oral formulations. BSP Pharmaceuticals is focused on innovative therapies such as Proteosome Inhibitors, ADCs , Liposomal formulations, handling the major platforms of ADC compounds currently in clinical and commercial phase.
Heraeus, the precious metals and technology group headquartered in Hanau, Germany, is a global, private company with 160 years of tradition. Our fields of competence include precious metals, materials, and technologies, sensors, biomaterials, and medical products, as well as dental products, quartz glass, and specialty light sources. With product revenues of €4.1 billion and precious metal trading revenues of €17.9 billion, as well as more than 12,900 employees in over 120 subsidiaries worldwide, Heraeus holds a leading position in its global markets.
Sartorius-Stedim Biotech is a key supplier of Bioprocessing technologies and Biomanufacturing related services.
Benefit from the most comprehensive bioprocess and single-use technology portfolio coupled with our process engineering expertise, ensuring a robust process development and manufacturing approach… Read more
MabPlex International provides one-stop, high-quality CRO/CMO solutions for biologics (mAb and ADCs) to our global clients. We are dedicated to help our clients accelerate development process and reduce manufacture costs. MabPlex has extensive experiences in manufacturing for therapeutic antibodies and antibody-drug conjugates (ADCs). Our manufacturing facilities with large-scale disposable lines and world-class instruments are operated by well-trained professionals in full compliance with U.S, European, and Chinese GMP regulations.